BioXcel Therapeutics, Inc. (BTAI) on Thursday reported positive topline results from a Phase 2 study evaluating BXCL501 for the treatment of opioid withdrawal symptoms in adults with opioid use disorder undergoing a methadone taper. Shares rose more than 12% in pre-market trading following the announcement.
The study indicated that BXCL501 may be as effective as or superior to Lucemyra, an FDA-approved non-opioid medicine, in reducing opioid withdrawal symptoms, while offering a more convenient dosing schedule and a favorable tolerability profile.
BXCL501 demonstrated similar or lower overall rates of cardiovascular side effects compared with lofexidine, and no cases of sedation or somnolence were reported in the BXCL501 groups, compared with 5% in the Lucemyra arm.
The findings build on earlier results from the Phase 1b/2 RELEASE study, which established the tolerability of selected BXCL501 doses in opioid-dependent patients. They also complement positive Phase 3 results for BXCL501 in treating acute agitation associated with bipolar disorder, schizophrenia and Alzheimer's disease.
BioXcel stock closed at $1.65 on Wednesday, up 3.13%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.